CN115350126A - Composition containing salicylic acid and having mild oil-controlling and acne-removing effects and application thereof - Google Patents
Composition containing salicylic acid and having mild oil-controlling and acne-removing effects and application thereof Download PDFInfo
- Publication number
- CN115350126A CN115350126A CN202211014572.6A CN202211014572A CN115350126A CN 115350126 A CN115350126 A CN 115350126A CN 202211014572 A CN202211014572 A CN 202211014572A CN 115350126 A CN115350126 A CN 115350126A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- acne
- salicylic acid
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title claims abstract description 128
- 206010000496 acne Diseases 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 85
- 230000000694 effects Effects 0.000 title claims abstract description 78
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960004889 salicylic acid Drugs 0.000 title claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 193
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 39
- 235000011511 Diospyros Nutrition 0.000 claims abstract description 37
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 37
- 241000124033 Salix Species 0.000 claims abstract description 37
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 37
- 239000001585 thymus vulgaris Substances 0.000 claims abstract description 37
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 25
- 240000006240 Linum usitatissimum Species 0.000 claims abstract description 21
- 235000004431 Linum usitatissimum Nutrition 0.000 claims abstract description 21
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 21
- 241000246358 Thymus Species 0.000 claims description 36
- 208000020154 Acnes Diseases 0.000 claims description 31
- 239000002537 cosmetic Substances 0.000 claims description 16
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 9
- 241000246044 Sophora flavescens Species 0.000 claims description 9
- 229940049292 n-(3-(dimethylamino)propyl)octadecanamide Drugs 0.000 claims description 4
- WWVIUVHFPSALDO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C WWVIUVHFPSALDO-UHFFFAOYSA-N 0.000 claims description 4
- 244000299790 Rheum rhabarbarum Species 0.000 claims 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 240000004980 Rheum officinale Species 0.000 abstract description 14
- 235000008081 Rheum officinale Nutrition 0.000 abstract description 14
- 241000186427 Cutibacterium acnes Species 0.000 abstract description 13
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 13
- 230000002195 synergetic effect Effects 0.000 abstract description 13
- 241000192125 Firmicutes Species 0.000 abstract description 6
- 230000008591 skin barrier function Effects 0.000 abstract description 2
- 240000002657 Thymus vulgaris Species 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 101
- 230000000052 comparative effect Effects 0.000 description 52
- 210000003491 skin Anatomy 0.000 description 50
- 238000002360 preparation method Methods 0.000 description 29
- 239000000839 emulsion Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- 238000013112 stability test Methods 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 11
- 238000010998 test method Methods 0.000 description 10
- 210000001061 forehead Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 210000002374 sebum Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 6
- 241000219061 Rheum Species 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 230000019612 pigmentation Effects 0.000 description 6
- QQGISFDJEJMKIL-JAIQZWGSSA-N (5z)-5-[[3-(hydroxymethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical group C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1CO QQGISFDJEJMKIL-JAIQZWGSSA-N 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010004950 Birth mark Diseases 0.000 description 2
- 208000014085 Chronic respiratory disease Diseases 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 244000148064 Enicostema verticillatum Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- 208000006787 Port-Wine Stain Diseases 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940107657 flaxseed extract Drugs 0.000 description 2
- 235000020704 flaxseed extract Nutrition 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 229940120668 salicin Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001521 two-tailed test Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 229950005578 tidiacic Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a mild composition containing salicylic acid and having oil-controlling and acne-removing effects and application thereof, wherein the composition comprises the following components in parts by weight: 5-15 parts of willow bark extract, 2-7 parts of radix sophorae flavescentis extract, 1-10 parts of Wisence GSS, 1-8 parts of polyhydric alcohol, 3-8 parts of persimmon leaf extract and 1-6 parts of thyme extract, and also can comprise 1-5 parts of rheum officinale extract, 1-7 parts of linseed extract and 2-8 parts of antibacterial peptide freeze-dried powder. The invention aims to provide a mild composition with synergistic components and special effects on controlling oil and recovering damaged acne muscle skin barriers, which can kill gram-positive bacteria in a synergistic manner, particularly propionibacterium acnes and inhibit the reproduction of the propionibacterium acnes.
Description
Technical Field
The invention belongs to the technical field of cosmetics, relates to a mild composition containing salicylic acid and having an oil-controlling and acne-removing effect, and also relates to an application of the mild composition containing salicylic acid and having the oil-controlling and acne-removing effect in cosmetics.
Background
Modern women pay great attention to skin care, however, acne dermatosis is a problem to be solved which troubles the public women for a long time. Comedones, blackheads, whiteheads, pimples, dark pox, acne and the resulting pigmentation, pox marks, pox pits, nodules, scars and the like seriously affect the psychology of the patient. The data show that the skin diseases of the acne are the most serious of teenager impairment diseases, cause psychological disorders to some people with weak heart, and have serious influence on later life, work and the like.
Acne, commonly known as acne, is a chronic inflammatory skin disease of the hair follicle sebaceous gland unit, can be affected in all age groups, and has a high juvenile onset rate. The incidence of acne has three components, firstly, the skin epidermis shows a 'vigorous' state, and the oil absorption towel is used for wiping the skin surface, so that the oil absorption towel can be clearly observed to absorb a lot of oil; then, if left uncontrolled, the vigorous secretory phase will continue and gradually decrease (as a result of the blockage of the hair follicles), with the appearance of sores or blemishes on the skin; if the interference is not continuously performed, the acne gradually develops into a white head, and the acne develops into various acnes along with the interference of external factors such as air, sunlight and the like. If no treatment is performed, microorganisms such as propionibacterium acnes can be detected at the acne part, and finally acne can be developed completely.
As can be seen from the acne forming step, oil control is the first step of skin care on normal skin, particularly oily skin or skin with vigorous secretion, effectively stops or controls the secretion of skin oil, and is the basis for keeping normal physiological functions of skin. Second, the formation of acne or comedo is the result of blocked follicular duct drainage, and an impermeable, blocked follicular duct must not prevent the formation of acne or comedones. The most critical step for normal skin without acne formation is not to block the pores. Finally, once acne is formed, symptomatic treatment is essential, and especially the killing of microorganisms such as propionibacterium acnes is the most critical step.
The acne-removing cosmetics sold on the market at present are mainly finished according to the mechanism: the salicylic acid is the most key component in acne-removing cosmetics, and the like, because the salicylic acid has a clear function of penetrating and blocking a hair follicle duct in medicine. Salicylic acid is currently added to formulations in two major forms, one being the salicylate and the other being present in the form of molecules. The pH of the formulation is generally above 5, while the optimum pH for salicylic acid treatment is below 4, with 3 being the optimum. Salicylic acid is an oil-soluble substance and hardly dissolved in water. Due to this property, salicylic acid molecules can penetrate the epidermis of the skin, rather than stay on the surface of the skin, and thus play a corresponding role. The form of the salicylic acid molecules present in the aqueous solution is particularly important. That is, the molecular form of salicylic acid in the formula is the basis for treating acne. The solvent is alcohol. And the following pain points exist in the process of treating the acne by using alcohol: 1) The formula containing alcohol can cause great irritation to the wound when being applied to the acne wound, and has obvious pain sensation and insusceptibility to tolerance; 2) Alcohol can stimulate skin hyperkeratosis, so that skin is easy to leave damaged symptoms such as pigmentation, acne marks, pockmarks, nodules, scars and the like; 3) The optimal treatment time for acne is delayed. Therefore, for the acne skin, it is very important and necessary to develop an effective composition for removing acne without causing the appearance of acne skin.
Disclosure of Invention
The invention aims to provide a composition of salicylic acid with oil control and acne removal effects, which has the characteristics of water solubility, low pH value and mildness, can effectively control oil, thoroughly block hair follicle ducts, does not leave capacitive symptoms and can kill microorganisms such as propionibacterium acnes.
The invention also aims to provide application of the composition containing salicylic acid and having the effects of controlling oil and removing acnes in cosmetics, and solves the problems of excessive skin oil secretion, hair follicle obstruction, acne mark and acne.
The technical scheme adopted by the invention is that the mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 5-15 parts of willow bark extract, 2-7 parts of radix sophorae flavescentis extract, 1-10 parts of Wisence GSS, 1-8 parts of polyhydric alcohol, 3-8 parts of persimmon leaf extract and 1-6 parts of thyme extract.
The solution according to the invention is also characterized in that,
also comprises 1 to 5 parts of rhubarb and 1 to 7 parts of flaxseed extract.
Also comprises 2 to 8 parts of antibacterial peptide freeze-dried powder.
7-12 parts of willow bark extract, 3-6 parts of radix sophorae flavescentis extract, 4-8 parts of Wisence GSS, 2-6 parts of polyhydric alcohol, 4-7 parts of persimmon leaf extract and 2-5 parts of thyme extract.
8-11 parts of willow bark extract, 4-5 parts of radix sophorae flavescentis extract, 5-7 parts of Wisence GSS, 3-5 parts of polyhydric alcohol, 5-6 parts of persimmon leaf extract, 3-4 parts of thyme extract, 2-4 parts of rheum officinale extract and 3-6 parts of linseed extract.
8-11 parts of willow bark extract, 4-5 parts of radix sophorae flavescentis extract, 5-7 parts of Wisence GSS, 3-5 parts of polyhydric alcohol, 5-6 parts of persimmon leaf extract, 3-4 parts of thyme extract, 2-4 parts of rhubarb extract, 3-6 parts of linseed extract and 4-7 parts of antibacterial peptide freeze-dried powder.
The Wisense GSS comprises the following components in percentage by mass: salicylic acid 40%, PEG-15 cocoamine 40%, stearamidopropyl dimethylamine 20%.
The invention adopts another technical scheme that the composition containing salicylic acid and having the effects of controlling oil and removing acnes is applied to cosmetics.
The beneficial effect of the invention is that,
(1) The composition disclosed by the invention is used by matching rheum officinale extract and linseed extract with willow bark extract, sophora flavescens extract, wisence GSS, polyhydric alcohol, persimmon leaf extract and thyme extract, realizes synergistic effect, realizes the increase of the retention time of the willow bark extract, the sophora flavescens extract, the Wisence GSS, the polyhydric alcohol, the persimmon leaf extract and the thyme extract on skin transportation, has special effects of controlling oil and removing acne, recovering damaged acne skin barrier and killing gram-positive bacteria in a synergistic manner, particularly has special effects of killing and inhibiting propionibacterium acnes and inhibiting the propagation of propionibacterium acnes, realizes the effect of 1+1 & gt 2, can be used for treating I-III acne, does not leave marks, has better effect on IV grade and has lower irritation;
(2) The antibacterial peptide freeze-dried powder in the composition can neutralize a certain acidic stimulation of salicylic acid, and the addition of other extracts can increase the solubility of the antibacterial peptide in water under the condition of not changing the action mechanism of the antibacterial peptide freeze-dried powder, can play a role in sterilization and bacteriostasis at an extremely low concentration, can synergically kill gram-positive bacteria, has a killing effect on partial viruses, fungi, protozoa, cancer cells and the like, even can improve the immunity and accelerate the wound healing process, and the anti-inflammation, bacteriostasis and wound healing in the acne removing process are all essential steps, so the antibacterial peptide freeze-dried powder is also an essential component in the components.
Detailed Description
The present invention will be described in detail with reference to the following embodiments.
The invention provides a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 5-15 parts of willow bark extract, 2-7 parts of radix sophorae flavescentis extract, 1-10 parts of Wisence GSS, 1-8 parts of polyhydric alcohol, 3-8 parts of persimmon leaf extract and 1-6 parts of thyme extract.
Also comprises 1 to 5 parts of rhubarb and 1 to 7 parts of flaxseed extract.
The antibacterial peptide freeze-dried powder is an active antibacterial peptide and contains small peptides such as lysozyme, nisin and the like, and can neutralize certain acidic stimulation of salicylic acid, and the addition of other extracts can increase the solubility of the antibacterial peptide in water under the condition of not changing the action mechanism of the antibacterial peptide freeze-dried powder, can play a role in sterilizing and inhibiting bacteria at an extremely low concentration, and can synergically kill gram-positive bacteria.
Further, the composition comprises the following components in parts by weight: 7-12 parts of willow bark extract, 3-6 parts of radix sophorae flavescentis extract, 4-8 parts of Wisence GSS, 2-6 parts of polyhydric alcohol, 4-7 parts of persimmon leaf extract and 2-5 parts of thyme extract.
Further, the composition comprises the following components in parts by weight: 8-11 parts of willow bark extract, 4-5 parts of radix sophorae flavescentis extract, 5-7 parts of Wisence GSS, 3-5 parts of polyhydric alcohol, 5-6 parts of persimmon leaf extract, 3-4 parts of thyme extract, 2-4 parts of rheum officinale extract and 3-6 parts of linseed extract.
Further, 8-11 parts of willow bark extract, 4-5 parts of radix sophorae flavescentis extract, 5-7 parts of Wisence GSS, 3-5 parts of polyhydric alcohol, 5-6 parts of persimmon leaf extract, 3-4 parts of thyme extract, 2-4 parts of rheum officinale extract, 3-6 parts of linseed extract and 4-7 parts of antibacterial peptide freeze-dried powder.
The components related in the composition are purchased through commercial channels, wherein willow bark extract, thyme extract, radix sophorae flavescentis extract and persimmon leaf extract are purchased from Jiamei biochemical products, inc. of Huzhou, polyhydric alcohol is purchased from Shanghai Yan Zhen commerce, inc., rhubarb extract is purchased from Nanjing dao Skov biotech, inc., antibacterial peptide freeze-dried powder is purchased from Shaanxi Huikang biotech, inc., and Wisence GSS and linseed extract are purchased from Shanghai Ruixi commerce, inc.
The preparation method of the mild composition containing salicylic acid and having the effects of controlling oil and removing acnes is characterized by weighing the components in parts by weight and stirring and mixing the components at normal temperature to obtain the composition.
The invention provides application of a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes in cosmetics, wherein the addition amount of the composition is 0.5-8.0% of the total mass of the cosmetics.
The Wisense GSS in the composition of the invention contains salicylic acid 40%, PEG-15 cocoamine 40% and stearamidopropyl dimethylamine 20%. The polyhydric alcohol is polyhydric alcohol, generally refers to water-soluble alcohols such as propylene glycol, 1,3-propylene glycol, methyl propylene glycol, 1,3-butanediol, 1,2-butanediol, pentanediol, glycerol and the like, and forms intermolecular hydrogen bonds under the synergistic action with PEG-15 cocoamine and stearamidopropyl dimethylamine in Wisense GSS, so that the hydration of salicylic acid in the Wisense GSS can be well increased, and the dissolution of the salicylic acid in water is enhanced; the salix bark extract mainly contains salicin which is a polymer of salicylic acid and glycosyl units, and can be slowly hydrolyzed into salicylic acid and saccharides in the presence of polyalcohol and Wisense GSS, and the salicin and the salicylic acid in the Wisense GSS form dynamic balance. The three have obvious pharmacological action, and the inhibition test result on the propionibacterium acnes is as follows: the original 1X 108 bacteria count, adding 1.0% and 2.0% extract, 1h after culture the residual bacteria count is 1.3X 104 and 2.3X 103, inhibition data shows, it is a powerful eliminating performance to Propionibacterium acnes, and can be used for preventing and treating acne. The sophora flavescens extract has the functions of resisting inflammation, inhibiting bacteria, nourishing and the like, which is very key for treating acne. The sophora flavescens extract has strong antibacterial activity, and the MIC (minimum inhibitory concentration) to gram-positive bacteria is between 25 and 50ng/mL (Propionibacterium acnes is gram-positive bacteria). The two-fold gradient dilution method is adopted to research the effect of matrine (prepared by extracting dried roots, plants and fruits of radix sophorae flavescentis with organic solvents such as ethanol) on acne bacteria, and the result shows that the matrine has strong inhibition effect on the acne bacteria, the minimum inhibitory concentration is 10mg/L, but the bactericidal effect is weak. But can be significantly improved by adding the persimmon leaf extract and thyme extract. This is because both of them have an activating effect on cathepsin (cathepsin is associated with inflammation of the skin, and low cathepsin indicates inflammation of the skin), thereby enhancing its bactericidal effect. The skin can be balanced and the secretion of grease can be controlled by the synergistic effect of the skin conditioner and other components, the skin can be conditioned to be in a balanced state, the hair follicle duct can be blocked thoroughly, the propionibacterium acnes and other microorganisms can be killed, and acne marks can not be left, so that the effects of controlling oil, removing acne and the like can be effectively realized.
Example 1
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 5 parts of willow bark extract, 2 parts of radix sophorae flavescentis extract, 1 part of Wisence GSS, 1 part of polyhydric alcohol, 3 parts of persimmon leaf extract and 1 part of thyme extract.
The invention provides a preparation method of a mild composition containing salicylic acid and having an oil-controlling and acne-removing effect.
Example 2
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 5 parts of willow bark extract, 2 parts of radix sophorae flavescentis extract, 1 part of Wisence GSS, 1 part of polyhydric alcohol, 3 parts of persimmon leaf extract and 1 part of thyme extract.
This example relates to the same preparation method as example 1.
Example 3
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 9 parts of willow bark extract, 5 parts of radix sophorae flavescentis extract, 6 parts of Wisence GSS, 5 parts of polyhydric alcohol, 6 parts of persimmon leaf extract and 4 parts of thyme extract.
This example relates to the same preparation method as example 1.
Example 4
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 12 parts of willow bark extract, 6 parts of radix sophorae flavescentis extract, 8 parts of Wisence GSS, 6 parts of polyhydric alcohol, 7 parts of persimmon leaf extract and 5 parts of thyme extract.
This example relates to the same preparation method as example 1.
Example 5
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acne, which comprises the following components in parts by weight: 15 parts of willow bark extract, 7 parts of radix sophorae flavescentis extract, 10 parts of Wisence GSS, 8 parts of polyhydric alcohol, 8 parts of persimmon leaf extract and 6 parts of thyme extract.
This example relates to the same preparation method as example 1.
Example 6
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 5 parts of willow bark extract, 2 parts of radix sophorae flavescentis extract, 1 part of Wisence GSS, 1 part of polyalcohol, 3 parts of persimmon leaf extract, 1 part of thyme extract, 1 part of rheum officinale extract and 1 part of linseed extract.
This example relates to the same preparation method as example 1.
Example 7
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 8 parts of willow bark extract, 4 parts of radix sophorae flavescentis extract, 5 parts of Wisence GSS, 3 parts of polyhydric alcohol, 5 parts of persimmon leaf extract, 3 parts of thyme extract, 2 parts of rheum officinale extract and 3 parts of linseed extract.
This example relates to the same preparation method as example 1.
Example 8
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 11 parts of willow bark extract, 5 parts of radix sophorae flavescentis extract, 7 parts of Wisence GSS, 5 parts of polyhydric alcohol, 6 parts of persimmon leaf extract, 4 parts of thyme extract, 4 parts of rheum officinale extract and 6 parts of linseed extract.
This example relates to the same preparation method as example 1.
Example 9
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acne, which comprises the following components in parts by weight: 15 parts of willow bark extract, 7 parts of radix sophorae flavescentis extract, 10 parts of Wisence GSS, 8 parts of polyhydric alcohol, 8 parts of persimmon leaf extract, 6 parts of thyme extract, 5 parts of rheum officinale extract and 7 parts of linseed extract.
This example relates to the same preparation method as example 1.
Example 10
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 5 parts of willow bark extract, 2 parts of radix sophorae flavescentis extract, 1 part of Wisence GSS, 1 part of polyhydric alcohol, 3 parts of persimmon leaf extract, 1 part of thyme extract and 2 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
Example 11
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 11 parts of willow bark extract, 5 parts of radix sophorae flavescentis extract, 7 parts of Wisence GSS, 5 parts of polyhydric alcohol, 8 parts of persimmon leaf extract, 4 parts of thyme extract and 7 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
Example 12
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 15 parts of willow bark extract, 7 parts of radix sophorae flavescentis extract, 10 parts of Wisence GSS, 8 parts of polyhydric alcohol, 8 parts of persimmon leaf extract, 6 parts of thyme extract and 8 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
Example 13
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 5 parts of willow bark extract, 2 parts of radix sophorae flavescentis extract, 1 part of Wisence GSS, 1 part of polyhydric alcohol, 3 parts of persimmon leaf extract, 1 part of thyme extract, 1 part of rheum officinale extract, 1 part of linseed extract and 2 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
Example 14
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acne, which comprises the following components in parts by weight: 8 parts of willow bark extract, 4 parts of radix sophorae flavescentis extract, 5 parts of Wisence GSS, 3 parts of polyhydric alcohol, 5 parts of persimmon leaf extract, 3 parts of thyme extract, 2 parts of rheum officinale extract, 3 parts of linseed extract and 4 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
Example 15
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 11 parts of willow bark extract, 5 parts of radix sophorae flavescentis extract, 5 parts of Wisence GSS, 7 parts of polyhydric alcohol, 6 parts of persimmon leaf extract, 4 parts of thyme extract, 4 parts of rheum officinale extract, 6 parts of linseed extract and 7 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
Example 16
The invention relates to a mild composition containing salicylic acid and having the effects of controlling oil and removing acnes, which comprises the following components in parts by weight: 15 parts of willow bark extract, 7 parts of radix sophorae flavescentis extract, 10 parts of Wisence GSS, 8 parts of polyhydric alcohol, 8 parts of persimmon leaf extract, 6 parts of thyme extract, 5 parts of rheum officinale extract, 7 parts of linseed extract and 8 parts of antibacterial peptide freeze-dried powder.
This example relates to the same preparation method as example 1.
The application also carries out a comparative experiment, and the specific comparative examples are as follows:
comparative example 1
A mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 8 parts of willow bark extract, 5 parts of Wisence GSS and 5 parts of persimmon leaf extract.
This comparative example relates to the same preparation method as example 1.
Comparative example 2
A mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 4 parts of sophora flavescens extract, 3 parts of polyalcohol and 3 parts of thyme extract.
This comparative example relates to the same preparation method as example 1.
Comparative example 3
A mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 8 parts of willow bark extract, 5 parts of Wisence GSS, 5 parts of persimmon leaf extract and 2 parts of rhubarb extract.
This comparative example relates to the same preparation method as example 1.
Comparative example 4
A mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 4 parts of sophora flavescens extract, 3 parts of polyalcohol, 3 parts of thyme extract and 3 parts of linseed extract.
This comparative example relates to the same preparation method as example 1.
Comparative example 5
A mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 8 parts of willow bark extract, 5 parts of Wisence GSS, 5 parts of persimmon leaf extract, 2 parts of rhubarb extract and 4 parts of antibacterial peptide freeze-dried powder.
This comparative example relates to the same preparation method as example 1.
Comparative example 6
A mild composition containing salicylic acid and having the effects of controlling oil and removing acnes comprises the following components in parts by weight: 4 parts of sophora flavescens extract, 3 parts of polyhydric alcohol, 3 parts of thyme extract, 3 parts of linseed extract and 4 parts of antibacterial peptide freeze-dried powder.
This comparative example relates to the same preparation method as example 1.
To verify the beneficial effects of the present invention, examples 1-16 and comparative examples 1-6 were tested, and the experimental data were as follows:
1. stability test
Cosmetics were prepared according to the composition of the components of examples 1 to 16 and comparative examples 1 to 6, respectively, and the stability thereof was examined, and the results are shown in Table 1.1, table 1.2, table 1.3 and Table 1.4.
TABLE 1.1 stability test results (unit: wt%) of examples 1 to 5
As can be seen from Table 1.1, the stability test results of examples 1-5 are all clear and stable.
TABLE 1.2 stability test results (unit: wt%) for examples 6 to 9
As can be seen from Table 1.2, the stability test results of examples 6 to 9 are both transparent and stable.
TABLE 1.3 stability test results (unit: wt%) for examples 10 to 16
As can be seen from Table 1.3, the stability test results of examples 10-16 are both clear and stable.
TABLE 1.4 stability test results (unit: wt%) for comparative examples 1 to 6
As can be seen from Table 1.4, the results of the stability tests of comparative examples 1,3 and 5 are transparent and unstable, and precipitation phenomenon occurs; comparative examples 2, 4, 6 the stability test results were all clear and stable.
2. Oil control efficacy test (in vitro method):
reference test method: intracellular lipid content determination
(1) Test samples: the test samples prepared by adding the compositions of examples 1 to 16 and comparative examples 1 to 6 to a general emulsion external base, and the blank control was the general emulsion external base. Wherein the compositions of examples 1 to 16 and comparative examples 2, 4 and 6 of the present invention account for 5% of the total mass of the emulsion the test method is an in vitro method and is suitable for evaluating cosmetics alleged to achieve an oil control effect by reducing the content of lipid in human sebaceous gland cells.
(2) The test method comprises the following steps: intracellular lipid content testing: laying SZ95 cells on a 96-well plate, culturing for 24h, replacing the SZ95 cells with a culture medium containing a detected sample with different concentrations, and fixing for 30min by using 4% paraformaldehyde after culturing for 24 h; OD490nm was then detected with oil red O staining kit. The results are shown in Table 2.
TABLE 2 intracellular lipid content
As can be seen from the results of the oil control test in Table 2, the oil control effects of examples 1-16 and comparative examples 2, 4 and 6 are all obvious, but the effects of examples 1-5 are weaker than those of examples 6-16, the intracellular lipid content can reach 24% at the lowest, and the oil control effects of all examples are better than those of all comparative examples. The differences in these effects are due to the different components and the different amounts of components added. This directly demonstrates that the synergistic cooperation between the components in the composition has a more effective and direct effect on oil control.
3. Acne treatment efficacy test (in vitro method)
(1) Test samples: the test samples prepared by adding the compositions of examples 1 to 16 and comparative examples 2, 4 and 6 to a common emulsion base for external use were used as a negative control and BPO gel (Sichuan Mingxin pharmaceutical industry, inc.). Wherein the compositions of the examples 1 to 16 of the invention and the comparative examples 2, 4 and 6 account for 8 percent of the total mass of the emulsion. Meanwhile, the common emulsion external matrix is used as a control group.
(2) The test method comprises the following steps: activating the freeze-stored Propionibacterium acnes, diluting the bacterial liquid to 1.0 × 10 6 CFU/mL. Adding 100 mu L of diluted bacterial liquid into a 96-well plate, and simultaneously adding 100 mu L of each sample solution; the negative control was 100. Mu.L of the common emulsion base solution and 100. Mu.L of BPO gel solution was added to the positive control. And placing the 96-well plate in an anaerobic box for incubation for 48 hours, taking out, and detecting OD600 of each hole by using an enzyme-labeling instrument to obtain the bacteriostasis rate of the propionibacterium acnes. The results are shown in Table 3.
TABLE 3 sample bacteriostasis rates
As can be seen from the acne removing test results in Table 3, the acne removing effects of examples 1-16 and comparative examples 2, 4 and 6 are obvious, but the effects of examples 1-5 are weaker than those of examples 6-16, and the differences of the effects are caused by different formulas and different addition amounts of the components of the formulas. But the acne removing effects of examples 1-16 were superior to all comparative examples. The highest bacteriostasis rate of the embodiment can reach 89 percent, while the highest bacteriostasis rate of the comparative example is 45 percent, which is almost half of the effect of the embodiment. The combination of the single components in the composition is proved, the bacteriostasis rate of the composition is far inferior to the bacteriostasis effect exerted by the synergy of the components, and the invention is proved to have great advantages in the aspect of bacteriostasis.
4. Human body safety inspection method
Methods refer to the skin-closed patch test as tested by the method of the skin patch test of human body section 2 of chapter seven of the technical Specification for cosmetic safety (2015 edition).
(1) Test samples: the test samples obtained by adding the compositions of examples 1 to 16 and comparative examples 2, 4 and 6 to a common emulsion external matrix were prepared, wherein the compositions of examples 1 to 16 according to the invention and comparative examples 2, 4 and 6 account for 0.5% of the total mass of the emulsion. Meanwhile, the common emulsion external matrix is used as a control group.
(2) The tester selects: volunteers between 18 and 60 years old who meet the requirements of the test are selected as subjects. The following conditions were not included as subjects: those who use antihistamines for nearly one week or immunosuppressants for nearly one month; in the last two months, any anti-inflammatory drug is applied to the tested part; the subject has a clinically unvulcanized inflammatory skin condition; insulin-dependent diabetic patients; patients suffering from asthma or other chronic respiratory diseases undergoing therapy; those receiving anti-cancer chemotherapy within approximately 6 months; patients with immunodeficiency or autoimmune disease; lactating or pregnant women; bilateral mastectomy and bilateral underarm lymph node resection; the judgment of the test result is influenced by scars, pigments, atrophy, port wine stains or other flaws on the skin to be tested; participation in other clinical trial investigators; those with high constitutional sensitivity; non-volunteer participants or those who cannot complete the prescribed content as required by the trial.
(3) The test method comprises the following steps: suitable subjects were selected as 50, 30 women and 20 men.
The selected area is not more than 50mm 2 And qualified spot test equipment with the depth of about 1 mm. The test sample is put into a small chamber of a spot tester, and the dosage is about 0.020g to 0.025g. The patch test device with the test sample is applied to the flexed side of the forearm of the subject with hypoallergenic tape, and is applied to the skin uniformly by pressing with the palm for 24 hours.
Skin reactions were observed at 30min (after disappearance of the indentation), 24h and 48h after removal of the test sample plaque tester, respectively, according to the criteria of table 3. And the observations were recorded and the results are shown in tables 4.1, 4.2.
TABLE 4.1 skin response grading Standard for skin Enclosed Patch test
TABLE 4.2 Patch test score Table
As can be seen from the patch results in Table 4.2, examples 1-16 and comparative examples 2, 4 and 6 all have certain irritability, examples 1-16 all show weak reactions of grade 1, and comparative examples 2, 4 and 6 show a wide range of reactions of grade 2 and a small number of reactions of grade 3, which indicates that although all have irritability, the comparative examples have much greater safety hazard than all the examples, the number of reactions of the examples is gradually reduced with the increase of time, and the number of reactions of grade 2 in the comparative examples is gradually increased with the increase of time, which may be caused by different components and proportions of comparative examples 2, 4 and 6. Combining the efficacy test and the safety test results, it can be seen that comparative examples 2, 4 and 6 have no significance in the effect although they show a certain effect in the oil control and acne treatment efficacy test, are far from the effects of the examples, have great hidden danger in human safety, and need further improvement if used as an acne treatment product.
5. Testing of oil control efficacy of human body
The oil control efficacy test method is referred to for the T ZHCA 002-2018 cosmetic.
(1) Test samples: the test samples prepared by adding the compositions of examples 1 to 16, comparative examples 2, 4, and 6 to a common emulsion external base, and the control was the common emulsion external base. Wherein the compositions of examples 1 to 16 of the present invention and comparative examples 2, 4 and 6 account for 5% of the total mass of the emulsion.
(2) Subject selection:
the number of subjects: effective subjects were 220, 10 per group. The age is between 18 and 65 years.
Cleaning face of volunteer with alkaline soap base cleaning product, and washing with clear waterThe scurf-free absorbent dry tissue is sucked dry, sits quietly in a standard-compliant test environment, exposes the forehead, keeps relaxed, and avoids touching the forehead. Measuring the amount of skin surface sebum on forehead by using Sebumeter for measuring skin surface sebum amount of forehead of more than 120 μ g/cm in 8h 2 The subject was obtained.
The following cases cannot be selected as subjects: those who affect sebum secretion when used in the near one month; those who use antihistamines for nearly one week or immunosuppressants for nearly one month; in the last two months, any anti-inflammatory drug is applied to the tested part; a subject having a clinically incurable inflammatory skin disease; insulin-dependent diabetic patients; patients suffering from asthma or other chronic respiratory diseases undergoing therapy; those who receive anti-cancer therapy within approximately six months; patients with immunodeficiency or autoimmune disease; lactating or pregnant women; bilateral mastectomy and bilateral underarm lymph node resection; the judgment of the test result is influenced by scars, pigments, atrophy, port wine stains or other flaws on the skin to be tested; participation in other clinical trial investigators; those with high constitutional sensitivity; non-volunteer participants or those who cannot complete the prescribed content as required by the trial.
(3) Measurement procedure
Preparation before testing
The test site was the forehead. The sample application area and the control area are randomly distributed on the left side and the right side of the forehead, the areas of the sample application area and the control area are consistent, the area of each area is at least 3cm multiplied by 3cm, the intervals of the areas are at least 1cm, and the sample application area and the control area are ensured to be balanced statistically.
Before formal test, the testee should sit still for at least 20min in a room meeting the standard, the testee cannot drink water and beverage, the forehead of the testee is exposed, and the testee is kept relaxed to avoid touching the tested part.
Measurement of
The test was performed according to the instructions of the skin surface sebum tester.
The determination method comprises the following steps: under the management of testers, testees clean the tested parts with an alkaline soap-based cleaning product, and the tested parts are washed clean with clear water and then are dried by using a non-scrap water-absorbing dry paper towel. Within 3min, the skin surface sebum amount of the sample application area and the control area were measured, respectively, 3 times at different positions in each area, and the measurement results were expressed as an average value of 3 measurements as an initial value.
The sample is (2.0 +/-0.1) mg/cm 2 The dosage of the latex is smeared for a single time, quantitative sampling is carried out through an injector or the equivalent, the latex finger stall is used for uniformly sampling in a specified area, and the actual smearing amount is recorded; respectively measuring 3 times at different positions in a sample smearing area and a control area at set measuring time points to obtain the skin fat amount on the surface of the skin in each area, wherein the measuring result is represented by the average value of the 3 times of measurement; the set measuring time point interval is not less than 1h, and the set time is 4h and 8h; when measuring at different measuring time points, avoiding the measured positions; during the test, the forehead of the subject is exposed, and the subject is prevented from touching the tested part; the test of the same subject must be completed by the same tester using the same instrument; when the cosmetics are tested, the control area is a blank control; during the time of sample use, such as adverse reaction of the subject's skin, the test should be immediately discontinued and the subject treated appropriately. Adverse reactions were recorded.
(4) Calculation results
Descriptive statistics
Descriptive statistics were performed on the measurements of the sample application area and the control area.
Differential analysis
And respectively calculating the difference between the initial values of the sample smearing area and the control area and the measured values at other time points, and then statistically analyzing the difference between the sample smearing area and the control area at different measuring time points by using the difference.
If the test data is normal distribution, performing statistical analysis by adopting a t test method; if the test data is in non-normal distribution, statistical analysis is carried out by a rank sum test method
The statistical method adopts two-tail test with test level alpha =0.05
(5) Determination of results
Positive results: compared with a control area, the difference value of the sebum measured value of the sample smearing area is remarkably different from P to 0.050, and the oil control effect of the tested product is shown;
negative results: compared with a control area, the difference value of the sebum measurement value of the sample smearing area is not significantly different from P and is more than or equal to 0.050, and the oil-free control effect of the tested product is shown;
the test results are shown in Table 5.
TABLE 5 measurement of skin oil content of the samples at 0h, 4h and 8h
Statistical analysis is carried out on the experimental results in the table 5, the skin oil content of the examples 1-16 is reduced by comparing with 0h for 4h and 8h, and the results are significantly different from those of a control group, wherein P is less than 0.001; illustrating that the formulations of examples 1-16, which were emulsions prepared with continued use of the compositions of the present invention, had an inhibitory effect on the oil content of the skin. The formulations of comparative examples 2, 4 and 6 had an inhibitory effect on the oil content of the skin. Compared with comparative examples 2, 4 and 6, the skin oil content of the examples 1 to 16 in 4h and 8h is higher than that of the examples 1 to 16 in the oil control effect than that of the comparative examples 2, 4 and 6. The components in the composition have synergistic effect and good oil control effect.
6. Human acne removing efficacy test
Reference (T/TDCA 004-2021) method
(1) Test samples: the compositions of examples 1 to 16, comparative examples 2, 4 and 6 were added to a common emulsion external base to prepare the resulting test samples. Wherein the compositions of the examples 1 to 16 and the comparative examples 2, 4 and 6 account for 8 percent of the total mass of the emulsion.
(2) Subject selection
The number of subjects: effective subjects were 220, 10 per group.
Using a front-to-back control: selection of eligible subjects by subject inclusion and exclusion criteria ensures that a final effective number of cases of no less than 10 persons per group are achieved.
Inclusion criteria
Healthy women or men between 18 and 40 years of age; a certain amount of dust on the facial skin cannot be nodules or cysts and the like which are difficult to improve by clinical preparations; no allergic diseases, no allergic history of cosmetics and other external preparations; the facial skin has no phenomena affecting the test, such as birthmarks, scratch marks, leukoplakia, pigmented nevi and the like; the trial process can be understood, voluntarily taking the trial and signing the written informed consent form.
Exclusion criteria
Women scheduled for pregnancy or lactation and within six months of postpartum; those with severe systemic disease, immunodeficiency or autoimmune disease; those who have taken antihistamines for the last week or immunosuppressants for the last month; those who used any anti-inflammatory drug on the test site in approximately two months; the tested part in the last three months participates in other clinical testers; patients suffering from respiratory diseases undergoing treatment; a person undergoing dermatological treatment; insulin dependent diabetes mellitus patients.
Subject restriction
During the test period, the test product and the control product provided by the test mechanism must be used by the test subject, and any other product with the functions of controlling oil and removing acnes, mildly treating the acnes or influencing the test result cannot be used;
the subjects should maintain a regular life, paying attention to a healthy diet during the trial.
(3) Test procedure
Test procedure
Self-front-back control test flow
At the first visit, subjects were instructed to perform the trial and signed written informed consent. Subjects were asked a series of questions about disease history, health status, etc. based on inclusion and exclusion criteria, etc., while facial acne status was assessed for compliance and recorded.
And (4) cleaning the face of a qualified test subject by using an alkaline soap-based cleaning product under the guidance of a worker, and wiping the face clean by using a non-dandruff absorbent dry paper towel after cleaning. Sit still in a satisfactory room for at least 30 minutes during which time water and beverages cannot be consumed.
The subjects were counted for facial acne by a dermatologist or laboratory researcher.
A standard image is taken with a skin image taking system. The image analysis software is used for analyzing a value of a of the skin of the tested part, and the smaller the value of a, the lighter the acne inflammation is, and the heavier the acne inflammation is.
The staff issues the test product to the testee and provides the instruction of the product, the using method of the product (including using position, using mode, using amount each time, using frequency, caution and the like) is determined, and the testee is ensured to use the product correctly and continuously until the end of the test period.
The subject returns to the laboratory at a set time point, under the same test conditions, the evaluation and the test are carried out according to the steps, a plurality of test time points can be set according to the product evaluation requirement, and the whole test period usually does not exceed 4 weeks.
At each return visit, the test product was taken back by the test subject and the amount of test product used was weighed and recorded.
During the use of the product, for example, adverse reactions on the skin of the subject, the test should be terminated immediately and the subject treated appropriately. Adverse reactions should be recorded.
(4) Calculation results
And performing normal distribution test after statistical analysis of data by using statistical analysis software, wherein the normal distribution test is in accordance with the normal distribution requirement, the self front and back comparison adopts paired t test, and otherwise, two related sample rank sum tests are adopted.
Statistical methods all used a two-tailed test with significance level α =0.05.
(5) Determination of results
The change result of any one of the relevant parameters of any visit time point visual assessment or image analysis before and after the product is used is obviously improved (P < 0.05), the acne removing efficacy of the test product is shown, otherwise, the test product is considered to have no acne removing efficacy, and the result is shown in table 6.
TABLE 6 VISIA-CR pox area ratio of test samples to D28 prior to use
Statistical analysis is carried out on the experimental results of the table 6, the area ratio of the acne on 28 days used in the examples 1-16 is reduced compared with the basic value before use, and the obvious difference is that p is less than 0.001, which shows that the formulas of the emulsions prepared by continuously using the composition disclosed by the invention in the examples 1-16 have obvious improvement effect on the acne problem of the skin; the reduction rate of the area ratio of the acne is obviously lower than that of the acne in the examples 1-16 in the comparative examples 2, 4 and 6, which shows that the acne removing effect of the examples 1-16 is better than that of the comparative examples 2, 4 and 6. In conclusion, the components in the composition have synergistic effect, so that the composition has a good acne removing effect and can achieve a lasting acne removing effect.
Table 7 compares a to D28 before use of the test samples
Statistical analysis of the results of the experiments in Table 7 shows that the surface red area a of 28 days used in examples 1-16 is reduced compared with the baseline value before use, and has significant difference, p is less than 0.001, which indicates that the formulas of emulsions 1-16 prepared by continuously using the composition of the present invention have significant effect on the improvement of skin inflammation; comparative examples 2, 4, 6 change in facial red area a significantly lower than examples 1 to 16, indicating that examples 1 to 16 have an improved effect on facial inflammation over comparative examples 2, 4, 6. In conclusion, the components in the composition have synergistic effect and good anti-inflammation and acne-removing effects.
7. Acne-removing pigment deposition test
(1) Test sample
The compositions of examples 1 to 16, comparative examples 2, 4 and 6 were added to a common emulsion external base to prepare the resulting test samples. Wherein the compositions of the examples 1 to 16 and the comparative examples 2, 4 and 6 account for 8 percent of the total mass of the emulsion.
(2) Application method
The test product was dispensed by the staff and instructions were given to the subjects based on the instructions to ensure that the subjects used the product correctly and continuously for 4 weeks.
(3) Selection of the subject
Eligible subjects were selected by subject inclusion and exclusion criteria, ensuring the final completion of 220 effective subjects, 10 per group.
Inclusion criteria
18-60 years old, healthy female or male; the tested part has at least one obvious acne mark; no allergic diseases, no allergic history of cosmetics and other external preparations; no history of photosensitive diseases exists in the past, and medicines influencing the photosensitivity are not used in the near term; the skin of the tested part has no phenomena of birthmarks, inflammations, scars, hirsutism and the like; the trial process can be understood, voluntarily taking the trial and signing the written informed consent form.
Exclusion criteria
Pregnant or lactating women, or those who have a pregnancy plan recently; patients with psoriasis, eczema, atopic dermatitis, severe acne, etc.; or those suffering from other chronic systemic diseases; the oral administration or external application of anti-inflammatory drugs such as corticosteroid hormone in about 1 month; the product or drug (such as hydroquinone preparation) which affects the skin color such as fruit acid, salicylic acid, etc. is used within 2 months; the experimental part is treated with vitamin A acid preparation or medical and aesthetic treatments such as chemical stripping, laser, pulse light and the like within nearly 3 months; inevitably exposed to sunlight for a long time; other clinical trial participants took place in approximately 2 months; other clinical assessments were not considered suitable for participants.
Subject restriction
During the test, the test product or the control product provided by a test mechanism is used at the tested part, and any other product with the effect of removing the pigmentation or possibly influencing the test result cannot be used; the test site should be well protected against sun exposure during the test period.
(4) Test sites: a face.
(5) The instrument equipment comprises: skin melanin detector: there are instruments that detect skin MI values based on the principle of spectral absorption.
(6) Test procedure
Volunteer subjects were enrolled as required and signed written informed consent. Before the test, the subjects are asked to have a series of problems about disease history, health conditions and the like according to the selection and exclusion standards and the like, and skin conditions such as acne pigment deposition on the test parts are evaluated and screened for conformity and recorded.
Evaluating and testing the skin basic value of the qualified subjects before using the product, including visual evaluation, instrument test and standard image shooting, and recording; the same evaluations and tests were again performed 4 weeks after the product was used. At the visit point, measuring the MI value of the skin in the acne pigment precipitation area of the test part of the test group by using a skin melanin tester, and testing each test area for three times and recording; the smaller the MI value of the test area, the lighter the skin tone and vice versa.
(7) Calculation results
Statistical analysis of data and normal distribution test are carried out by applying statistical analysis software, the normal distribution requirement is met, the self front and back comparison adopts pairing t test, otherwise, two related sample rank sum tests are adopted; comparing the grade data before and after use, and performing rank sum inspection on two related samples; the comparison between test product and control group was done using independent sample t test or rank-sum test. The above statistical analyses were all two-tailed tests with significance level α =0.05.
And (3) if the change results of any one of the relevant parameters of any visit time point visual evaluation, instrument test or image analysis before and after the product is used are different remarkably (P is less than 0.05), the test product is determined to have the efficacy of removing acne mark pigmentation, otherwise, the test product is determined to have no efficacy of removing acne mark pigmentation, and the results are shown in a table 8.
TABLE 8 MI of the test specimens measured before use and D28
Statistical analysis of the experimental results in Table 8 shows that the MI value of the face of 28 days used in examples 1-16 is reduced compared with the basic value before use, and has significant difference, p is less than 0.001, which indicates that the formulas of the emulsions prepared by continuously using the composition of the invention in examples 1-16 have significant improvement effect on acne mark deposition on the skin; the decrease rate of MI values of comparative examples 2, 4 and 6 was significantly lower than that of examples 1 to 16, indicating that examples 1 to 16 had better effect of improving pigmentation than comparative examples 1 to 6. The components in the composition have synergistic effect and good acne removing pigment deposition effect.
In conclusion, the synergistic effect among the willow bark extract, the sophora flavescens extract, the Wisence GSS, the polyhydric alcohol, the persimmon leaf extract, the thyme extract, the rheum officinale extract, the linseed extract and the antibacterial peptide freeze-dried powder achieves the expected result in stability test, oil control and acne treatment efficacy test, and the composition can more effectively and more powerfully remove acnes and leave no acne marks on the basis of no skin damage, and the composition plays a better role in a comparative ratio under the synergistic effect and keeps the original advantages to a certain extent, so that the advantages of salicylic acid are amplified and the defects of the salicylic acid are overcome.
Claims (8)
1. The mild composition containing salicylic acid and having the effects of controlling oil and removing acnes is characterized by comprising the following components in parts by weight: 5-15 parts of willow bark extract, 2-7 parts of radix sophorae flavescentis extract, 1-10 parts of Wisence GSS, 1-8 parts of polyhydric alcohol, 3-8 parts of persimmon leaf extract and 1-6 parts of thyme extract.
2. The mild composition with oil-controlling and acne-removing effects containing salicylic acid according to claim 1, further comprising 1-5 parts of rhubarb and 1-7 parts of linseed extract.
3. The composition containing salicylic acid and having the effects of controlling oil and removing acnes as claimed in claim 1 or 2, further comprising 2-8 parts of antibacterial peptide lyophilized powder.
4. The composition containing salicylic acid and having the effects of controlling oil and removing acne as claimed in claim 1, wherein the composition comprises 7-12 parts of willow bark extract, 3-6 parts of radix sophorae flavescentis extract, 4-8 parts of Wisence GSS, 2-6 parts of polyhydric alcohol, 4-7 parts of persimmon leaf extract and 2-5 parts of thyme extract.
5. The mild salicylic acid-containing composition with oil-controlling and acne-removing effects according to claim 2, wherein the willow bark extract is 8-11 parts, the sophora flavescens extract is 4-5 parts, the Wisence GSS is 5-7 parts, the polyalcohol is 3-5 parts, the persimmon leaf extract is 5-6 parts, the thyme extract is 3-4 parts, the rhubarb extract is 2-4 parts, and the linseed extract is 3-6 parts.
6. The composition containing salicylic acid with mild oil-controlling and acne-removing effects as claimed in claim 3, wherein the willow bark extract is 8-11 parts, radix sophorae flavescentis extract is 4-5 parts, wisence GSS is 5-7 parts, polyalcohol is 3-5 parts, persimmon leaf extract is 5-6 parts, thyme extract is 3-4 parts, rhubarb extract is 2-4 parts, linseed extract is 3-6 parts, and antimicrobial peptide freeze-dried powder is 4-7 parts.
7. The mild salicylic acid-containing composition with oil-controlling and acne-removing effects according to any one of claims 1-6, wherein the Wisence GSS comprises the following components in percentage by mass: 40% of salicylic acid, 40% of PEG-15 cocoamine and 20% of stearamidopropyl dimethylamine.
8. Use of a mild and oil-and acne-controlling composition according to any of claims 1-6 containing salicylic acid in cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211014572.6A CN115350126B (en) | 2022-08-23 | 2022-08-23 | Mild salicylic acid-containing composition with oil control and acne removal effects and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211014572.6A CN115350126B (en) | 2022-08-23 | 2022-08-23 | Mild salicylic acid-containing composition with oil control and acne removal effects and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115350126A true CN115350126A (en) | 2022-11-18 |
| CN115350126B CN115350126B (en) | 2024-03-26 |
Family
ID=84002429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211014572.6A Active CN115350126B (en) | 2022-08-23 | 2022-08-23 | Mild salicylic acid-containing composition with oil control and acne removal effects and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115350126B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120315235A1 (en) * | 2011-06-08 | 2012-12-13 | Scott Alan Weisenfluh | Emu oil in combination with other active ingredients for treating skin imperfections |
| CN108403582A (en) * | 2018-04-08 | 2018-08-17 | 北京皓尔生物科技有限公司 | A kind of anti-acne, acne-removing composition and its application containing antibacterial peptide |
| CN109172399A (en) * | 2018-10-24 | 2019-01-11 | 广州科颜氏药妆生物科技研发中心（有限合伙） | A kind of acne-removing and skin-clearing composition |
| CN109674668A (en) * | 2019-01-21 | 2019-04-26 | 秋臣化妆品有限公司 | A kind of anti-acne draft stoste and preparation method thereof |
| CN112006956A (en) * | 2020-09-04 | 2020-12-01 | 广州莱梧生物科技有限公司 | Acne-removing cream and preparation process thereof |
| KR20210029359A (en) * | 2019-09-06 | 2021-03-16 | 이승창 | Cosmetic composition for improving acne |
-
2022
- 2022-08-23 CN CN202211014572.6A patent/CN115350126B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120315235A1 (en) * | 2011-06-08 | 2012-12-13 | Scott Alan Weisenfluh | Emu oil in combination with other active ingredients for treating skin imperfections |
| CN108403582A (en) * | 2018-04-08 | 2018-08-17 | 北京皓尔生物科技有限公司 | A kind of anti-acne, acne-removing composition and its application containing antibacterial peptide |
| CN109172399A (en) * | 2018-10-24 | 2019-01-11 | 广州科颜氏药妆生物科技研发中心（有限合伙） | A kind of acne-removing and skin-clearing composition |
| CN109674668A (en) * | 2019-01-21 | 2019-04-26 | 秋臣化妆品有限公司 | A kind of anti-acne draft stoste and preparation method thereof |
| KR20210029359A (en) * | 2019-09-06 | 2021-03-16 | 이승창 | Cosmetic composition for improving acne |
| CN112006956A (en) * | 2020-09-04 | 2020-12-01 | 广州莱梧生物科技有限公司 | Acne-removing cream and preparation process thereof |
Non-Patent Citations (2)
| Title |
|---|
| 何陵玲;张毅;龚秋君;张青;: "痤疮的机理症状及祛痘型护肤品功效类型", 日用化学工业, no. 05, pages 336 - 342 * |
| 项蕾红;马英;: "痤疮治疗的进展", 皮肤性病诊疗学杂志, no. 04, pages 227 - 231 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115350126B (en) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lowe et al. | Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients | |
| CA2453823C (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| EP3520796A1 (en) | Composition containing water-solubilized ursodeoxycholic acid for preventing or treating inflammatory skin disease or serious pruritus | |
| EP0738516A1 (en) | External preparation for skin protection | |
| CN108272740B (en) | Composition and acne containing the composition repair cosmetics | |
| CN111956637B (en) | Acne-removing ointment and preparation method thereof | |
| Kusuma et al. | Formulation and evaluation of anti acne gel containing citrus aurantifolia fruit juice using carbopol as gelling agent | |
| CN111773272A (en) | External compound formula for treating acne and preparation method thereof | |
| CN111743830A (en) | Acne-removing composition and application thereof | |
| CN111588815B (en) | External acne-removing traditional Chinese medicine composition, application thereof and acne-removing balancing essence containing composition | |
| CN115919733A (en) | Cosmetic composition for removing acne and preparation method thereof | |
| Bartenjev et al. | Topical effectiveness of a cosmetic skincare treatment for acne-prone skin: a clinical study | |
| CN112516066B (en) | Oil control composition and application thereof in cosmetics | |
| KR19990079378A (en) | Cosmetics containing natural products that are effective in treating and preventing acne | |
| Moglia et al. | Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses | |
| Schölermann et al. | Efficacy and safety of Eucerin 10% urea lotion in the treatment of symptoms of aged skin | |
| CN115350126B (en) | Mild salicylic acid-containing composition with oil control and acne removal effects and application thereof | |
| CN115414282A (en) | Composition containing ultramicro azelaic acid with acne-removing, anti-inflammatory, whitening and freckle-removing effects | |
| Khee et al. | The efficacy and safety of a 70% glycolic acid peel with vitamin C for the treatment of acne scars | |
| CN112933024A (en) | Repair face cream containing industrial hemp extract and preparation method thereof | |
| CN111939097A (en) | Moisturizing and allergy-relieving composition and application thereof | |
| CN115844796A (en) | Water-in-oil composition with acne removal, skin rejuvenation and slow release effects and application | |
| CN116077385A (en) | Skin care composition containing Ruipage and application thereof | |
| CN114306116A (en) | Skin-brightening cream for sensitive muscles and preparation method thereof | |
| Suresh et al. | Clinical Evaluation of Modified Manashiladi Lepa in the prevention of post-surgical scar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |